fbpx
Hot Off the Press: The DCB Annual Report 2022/23 is Out Now!

Hot Off the Press: The DCB Annual Report 2022/23 is Out Now!

Hot Off the Press: The DCB Annual Report 2022/23 is Out Now!

In the fiscal year 2022/23, the DCB has made significant progress towards their strategy and vision thanks to the great commitment of all employees. The DCB Annual Report has now been published and you can read more about the projects, teams and their achievements of 2022/23.

The DCB – An Internationally Recognised Centre for Diabetes Technology

The DCB has made significant achievements in meeting the 5-year goals. The holocratic structure, in which the individual teams are responsible for their own work and projects and are given the corresponding freedom, has helped a great deal.

The ongoing support from the board of directors and from Willy Michel as the benefactor has allowed the DCB to further advance their development.

The DCB is now collaborating with around 100 start-ups from more than 30 countries. This number demonstrates that the Diabetes Center Berne has gained recognition beyond national borders and is being perceived internationally as a centre for diabetes technology. 

Prof. Dr. Lilian Witthauer and her team in the field of Smart Sensing and Prof. Dr. José Garcia and his team in the field of Closed-Loop Systems have successfully established themselves and are working on specific projects to sustainably improve the lives of people with diabetes.

The close collaboration with our associated research groups allows the DCB to actively promote and support the translation of research projects into user-oriented and market-oriented solutions.”

– Derek Brandt, CEO

Download the full report now!

Download the full report now!

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

Start-up funding in diabetes technology: DCB Innovation Challenge enters new round 

Start-up funding in diabetes technology: DCB Innovation Challenge enters new round 

Start-up funding in diabetes technology: DCB Innovation Challenge enters new round 

For the third time, the Diabetes Center Berne is launching the Open Innovation Challenge with the aim of specifically promoting innovative projects in the field of diabetes management on Swiss and international level. Participating start-ups benefit from professional expert feedback, and the three best projects in each of the categories Diabetes Devices and Digital Diabetes receive access to a bootcamp. The finalists will receive prize money of up to USD 100,000 and further support from the DCB. The DCB Innovation Challenge is the world’s largest diabetes technology award with international appeal.

More than 537 million people worldwide live with diabetes, which means a constant challenge in everyday life for those affected. Technological innovations make an important contribution to making it easier to deal with diabetes – whether it is measuring glucose levels or now even planning the amount of insulin needed via an app. But despite these enormous advances in diabetes technology, there is still a great, unmet need for innovative technical solutions. These should help to ease the challenge for users in everyday life and improve the lives of people with diabetes in the long term.

Two categories: Diabetes Devicesand “Digital Diabetes

In the last edition of the Open Innovation Challenge 2022, start-ups GO-Pen from Denmark and Una Health from Germany were named winners in their respective categories. GO-Pen is developing a cost-effective, reliable and sustainable insulin pen, while Una Health enables people with type 2 diabetes to understand the causes of their condition and make simple and targeted changes to improve their health.

In the new edition of the Innovation Challenge 2023, there are again two categories: on the one hand for medical devices, such as insulin pens, insulin pumps or sensors for continuous glucose measurement. The other is for digital solutions such as apps for diabetes management, which can include monitoring glucose levels, nutrition and exchanging information with other people with diabetes. For the category “Diabetes Devices”, the kick-off will be at the beginning of May 2023, “Digital Diabetes” will start at the beginning of June 2023. After a first round and feedback from the expert jury, the top 20 will enter a mentoring programme. The three best projects will be invited to a bootcamp individually tailored to them. On 9 November 2023, the winning project will be selected by an international jury and rewarded with 100,000 USD including in-kind support such as coaching. Second and third place will each receive USD 20,000 including further support. The DCB Open Innovation Challenge is thus the world’s largest diabetes technology award with international appeal. Start-ups, medical and research professionals, but also individuals can apply.

Closing gaps with a translational approach

“At the DCB, we want to close the gaps between ideas, clinical trials and start-ups through innovation.  We are also pursuing this goal with the DCB Open Innovation Challenge, which connects start-ups, mentors, corporates and the international diabetes community. In this way, we can help real innovative ideas in diabetes management to achieve a breakthrough. Not only with funding, but also with targeted support from our partner network,” says Dr Maren Schinz, responsible for the DCB Open Innovation Challenge.

Do you have an innovative idea to facilitate change diabetes management forever? Want to see how your idea becomes reality? Do you have valuable insights to help co-create the diabetes technology of tomorrow? Do you have feedback to share with others in the community? Then sign up to our Innovation Platform and participate in the DCB Open Innovation Challenge 2023! You can find more information here.

Media release

PDF, 437.68 KB

Innovation Challenge 2023

Information sheet

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

SDVF is part of the ADA Innovation Challenge expert panel 

SDVF is part of the ADA Innovation Challenge expert panel 

SDVF is part of the ADA Innovation Challenge expert panel 

The Swiss Diabetes Venture Fund (SDVF), which DCBs CEO Derek Brandt is general partner of, will be part of the expert panel of the Diabetes Innovation Challenge run by the American Diabetes Association (ADA). The Innovation Challenge will be part of the 83rd Scientific Sessions from June 23–26 in San Diego, CA.

For their Innovation Challenge, the ADA is welcoming emerging companies to pitch pioneering ideas in support of improving the lives of people living with diabetes. Five finalists will be selected to present in front of a live audience at the ADA’s Scientific Sessions in San Diego. 

 The three winning start-ups will be selected by the audience and the panel of expert judges from the Swiss Diabetes Venture Fund, The Helmsley Charitable Trust, and StartUp Health. Winners will earn an opportunity to attend a private event with the three judges and the Chief Scientific and Medical Officer of ADA, Dr. Robert Gabbay immediately following the presentation.  

Applications are open until 5 May. More information can be found here.

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB to support T1D1 – an app by the youngest participant of the Open Innovation Challenge

DCB to support T1D1 – an app by the youngest participant of the Open Innovation Challenge

DCB to support T1D1 – an app by the youngest participant of the Open Innovation Challenge

Berne and Washington D.C. – Today, DCB announced a collaboration with T1D1 (Type 1 From Day 1), an app by teenager Drew Mendelow. After his diagnosis with type 1 diabetes in 2020, the now 16-year old designed and built a mobile app to simplify diabetes management from day one of diagnosis. DCB is going to support the project with know-how and financial resources to develop the documentation needed to submit the T1D1 APP for approval with the FDA (US) as well as the European Union under the Medical Device Regulations (MDR).

The app currently has over 45,0000 downloads primarily in the US. The approval is necessary to continue usage and to be able to offer an adequate app solution for more people with diabetes in the future, both in Europe and in the US.

“We from the DCB are excited to be able to help a teenager maintaining his solution on the market – a solution from a person living with diabetes for people with the same needs”, said Derek Brandt, CEO of the Diabetes Center Berne.

Drew Mendelow (Founder of T1D1) at the DCB Start-Up Night 2023

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland

DCB Open Innovation Challenge: GO-Pen and Una Health emerge as winners of 2022

DCB Open Innovation Challenge: GO-Pen and Una Health emerge as winners of 2022

DCB Open Innovation Challenge: GO-Pen and Una Health emerge as winners of 2022

On November 30, this year’s DCB Start-Up Night and Award Ceremony of the Open Innovation Challenge 2022 took place. After an exciting evening of pitching, an international jury chose the winners of the second edition of the Innovation Challenge, which this year was split up into the two categories “Diabetes Devices” starting in spring, and “Digital Diabetes” starting in summer.

 

66 ideas from 22 countries were submitted to the Challenge, with three finalists in each category. These six finalists from the U.S, Denmark, France, Australia, and Germany pitched their projects live on stage in Bern in front of a hundred guests and a large fan community watching online. The first prizes of each 100.000 USD in funding and in-kind support went to GO-Pen (Denmark) in the category Diabetes Devices and to Una Health (Germany) in the category Digital Diabetes.

Simon Michel (Board Member DCB), Derek Brandt (CEO DCB) and Ole Kjerkegaard Nielsen (CEO Go-Pen)

GO-Pen is developing an affordable, reliable and sustainable insulin pen. Their vision is to make a difference for the millions of people living with diabetes who currently cannot afford modern devices. Derek Brandt, CEO of Diabetes Center Berne said:

“The innovation, the need in the market and the business model convinced the jury in their decision. GO-Pen has clearly defined target markets. For example, about 4 million people in the USA still use standard syringes for injecting insulin every day. This is exactly where GO-Pen wants to come in with its solution and provide those affected with a solution that allows for a simpler and more precise dosage of insulin, but hardly increases the costs compared to a conventional syringe. This solution can also provide significant added value for people with diabetes in low and middle income countries. Especially in these regions, the number of people affected is rapidly increasing.”

Pascal Grimm (CEO Una Health) and Dr. Katarina Braune (Jury Member)

Una Health, winner of the category Digital Diabetes, enables people with type 2 diabetes to understand what is driving their condition and to make simple, targeted changes to improve their health sustainably. For this, biosensor and lifestyle data are combined with behavioral science-based change models in a user centered certified mobile app.

“What has caused my blood sugar to spike? This is a question that people with type 2 diabetes frequently ask themselves. That’s where Una Health comes in and has developed an approach in which people with type 2 diabetes learn via an app and the use of continuous glucose sensors how food and their behaviour affect their blood glucose; this with the aim of improving blood glucose in the long term. The goal is clear: control over blood sugar also means more control over the quality of life of the person affected. The jury is convinced that continuous learning and understanding of the correlations will sustainably improve the long-term prognosis of people with diabetes and in this case type 2 diabetes.”

said Derek Brandt.

The two winners were awarded with 100.000 USD each, consisting of 60.000 USD in funding and 40.000 USD in in-kind support (services provided by DCB and its partner network). The four remaining finalists received 20.000 USD each, consisting of 10.000 USD in funding and 10.000 USD in in-kind support:

Diabetes Devices

BOYDSense  (Germany): BOYDSense gives people access to gentle, non-invasive health monitoring starting with diabetes. They leverage molecules (volatile organic compounds) present in exhaled breath correlated with glucose biomarkers to accurately calculate the glucose value in real-time and a very user-friendly way.

Diatech Diabetes (U.S.): SmartFusion is an infusion monitoring platform for people with insulin pumps and automated insulin delivery devices. Their technology works by analyzing historical and real-time data from insulin pumps + continuous glucose monitors to better detect the occurrence of infusion set failure and reduce severe hyperglycemia from insulin dosing.

Digital Diabetes

Balance Health (Australia): Balance Health is taking patient engagement and centricity to the next level. A level where the clinician and the patient can collaborate to determine what CGM alerts the patient would like to receive  and  how  often.  This proprietary knowledge  acquisition  approach that  they are developing means that a patient will feel like they have their clinician checking their CGM data daily and messaging them if there is something worthwhile to share.

EkiYou (France): What if people with diabetes had in their pocket: A super calculator for insulin doses, access to dieticians/nurses to ask questions and access to a community of patients to share their experience? They would increase their time in range, would feel less anxious about their disease and would personalise their treatment in an autonomous way.

About the DCB Open Innovation Challenge

After the initial launch in 2021, the DCB Open Innovation Challenge took place for the second time this year. The aim of the Challenge is to promote innovative, international projects in the field of diabetes management. With a total prize money of 280.000 USD, the DCB Open Innovation Challenge is one of the world’s most generous international awards in the area of diabetes. Applications are open to start-ups, medical and research professionals, and individuals.

Stage and audience at the DCB Start-Up Night 2022

Ben Delhey (CEO BOYDSense) pitching live on stage

John Wilcox (CEO Diatech Diabetes) on stage in Berne

Pete Lomas (CEO Balance Health) during his pitch

Omar Diouri (CMSO EKiYou) on stage in Berne

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Open Innovation Challenge: The top 3 devices have been selected

DCB Open Innovation Challenge: The top 3 devices have been selected

DCB Open Innovation Challenge: The top 3 devices have been selected

The DCB Open Innovation Challenge 2022 has reached its next stage as the DCB Innovation Jury has selected the top 3 teams of the category Diabetes Devices.

The jury together with finalist John Wilcox during the pitch day. Photo: André Raul Surace

Of the TOP 20 teams that pitched their idea to the DCB Innovation Jury last Tuesday, the following three teams were selected for the finals:

Ole Kjerkegaard Nielsen (DK) – GO-Pen: Affordable insulin pen for all

We believe everybody should have equal access to quality diabetes care. The GO-PEN(TM) is a refillable insulin pen that works with a broad range of insulins and provides the same advantages as any prefilled insulin pen compared to injecting insulin from vials using syringes.

John Wilcox (US) – SmartFusion: A Next Generation Insulin Infusion Monitoring Platform

SmartFusion is an infusion monitoring platform for people with insulin pumps and automated insulin delivery devices. Our technology works by analyzing historical and real-time data from insulin pumps + continuous glucose monitors to better detect the occurrence of infusion set failure and reduce severe hyperglycemia from insulin dosing.”

Ben Delhey (FR) – Lassie: The first non-invasive breath analyzer for people with diabetes

We give people access to gentle non invasive health monitoring starting with Diabetes. We leverage molecules (Volatile organic compounds) present in exhaled breath and correlated with glucose biomarker to calculate accurately the value of Glucose in real-time and very user-friendly way.”

The three finalists will attend a one-week innovation bootcamp in Switzerland in the end of June. The final pitches and award ceremony will take place on 30 November 2022 at the sitem-insel in Bern together with the top 3 teams of the category Digital Diabetes starting mid-July. The three winning teams will receive a total price of 200,000 US dollars, along with additional support. The DCB Innovation Challenge award is one of the world’s most generous and renowned diabetes-related awards.

The DCB Innovation Jury during Pitch Day on 10 May 2022. Photos: André Raul Surace

Downloads

More recent news

Sign up for our newsletter and stay up to date.

* Pflichtfelder
DSGVO *

DCB Research AG

Freiburgstrasse 3
3010 Bern
Switzerland